

Current level of influenza activity: Low

Influenza activity trend: Decreasing


Confirmed influenza cases since 2023 Week 40: 4283 (473 influenza A(H3N2), 1009 influenza A(H1N1)pdm09, 2392 influenza A untyped and 509 influenza B)

During Week 16 (ending 21/04/2024) there were 34 cases of influenza confirmed, with three cases from previous weeks. Influenza is still circulating, although overall activity has decreased. COVID-19 cases have decreased in recent weeks. RSV activity in children under 5 years remains at baseline intensity levels. Additionally, recent weeks have seen increases in mycoplasma, rhinovirus, adenovirus, and parainfluenza.

- The **Sentinel GP consultation rate for influenza-like illness (ILI)** in Wales during Week 16, was 5.0 consultations per 100,000 practice population (Table 1). The rate remained relatively stable compared to the previous week (4.9 consultations per 100,000. Figure 1).
- The **Sentinel GP consultation rate for Acute Respiratory Infections (ARI)** was 190.0 per 100,000 practice population during Week 16 (Table 2 and Figure 3). This is a decrease compared to the previous week (212.7 per 100,000). During week 16, Lower Respiratory Tract Infections decreased to 73.4 per 100,000 and Upper Respiratory Tract Infections also decreased to 117.5 per 100,000 compared to the previous week.
- The percentage of calls to **NHS Direct Wales** which were 'influenza-related' (cold/flu, cough, fever, headache, and sore throat) during Week 16 decreased to 16.8% (Figure 13).
- During Week 16, 1,204 specimens received multiplex respiratory panel testing from patients attending hospitals. **18 tested positive for influenza (six influenza A(not subtyped), seven influenza A(H1N1), and five influenza B).** Overall influenza test-positivity decreased to 1.5% from 2.6%. In those aged under 18 positivity decreased to 1.9% from 2.7%, and in those aged over 18 it decreased to 1.3% from 2.6%. In addition, there were: 195 rhinovirus, 79 adenovirus, 75 mycoplasma, 55 human metapneumovirus, 40 SARS-CoV-2, 36 parainfluenza, 20 seasonal coronaviruses, 18 enterovirus and five RSV positive samples (Figure 5). Additionally, 295 samples from patients were tested for influenza, RSV and SARS-CoV-2 only. Of these 295 samples there were **nine influenza A, four influenza B**, 34 for SARS-CoV-2, and one RSV. (Figure 7). Furthermore, during week 16, 50 respiratory specimens were tested from patients in intensive care units (ICU) of which none was positive for influenza (Figure 8).
- There were 107 surveillance samples from patients with ILI symptoms collected by **sentinel GPs and community pharmacies** during Week 16. Of the 107 samples, **three tested positive for influenza (one influenza A(H3N2), one influenza A(H1N1) and one A untyped)**, 19 mycoplasma, 14 rhinovirus, eight parainfluenza, three adenovirus, three human metapneumovirus, three enterovirus, three coronavirus, two bocavirus and one SARS-CoV-2 as at 24/04/2024 (Figure 4).
- From all samples where influenza subtyping information was immediately available during week 16, one was influenza A(H3), eight were influenza A(H1N1), five were influenza B and seven influenza A(not subtyped) (Figure 6). *Additional typing is carried out on all confirmed influenza A samples where typing results are not available from first-line testing, the additional information from these tests will be added to case totals after the end of the season.*
- **Confirmed RSV case incidence in children aged under 5, has further decreased and remains at baseline intensity levels (compared to historic levels before 2021).** In week 16 there were 1.9 confirmed cases per 100,000 in this age group (Figure 9).
- The 7-day rolling sums of cases hospitalised within 28 days of an influenza or RSV positive test result in the community (or up to two days post-admission) were 18 and three respectively during Week 16 (Figures 10 & 11) and 16 for SARS-CoV-2 during week 16 (Figure 12).
- During week 16, no **ARI outbreaks** were reported to the Public Health Wales Health Protection team.
- According to [EuroMoMo](#) analysis, all-cause deaths in Wales were not in excess during week 15.
- As at 09/04/2024, uptake of influenza vaccination was 72.4% in adults aged 65 years and older, 39.1% in those aged 6 months to 64 years at clinical risk, 42.9% in two- and three-year-old children, 61.9% in children aged four to 10 years and 49.7% in children aged 11 to 15 years (Table 3).

Respiratory infection activity in Wales


Figure 1. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (as of 21/04/2024).



* The Moving Epidemic Method (MEM) threshold calculated for Wales ILI consultation rates is 11.1 per 100,000. MEM thresholds used in this chart are based on influenza from 2010-11 to 2018-19 seasons. Caution should be used when comparing consultation rates from March 2020 onwards to previous periods due to the changes in health-seeking behaviours brought about by the COVID-19 pandemic.

**Clinical consultations for ILI seasons are monitored from W40 to W40, the most recent data is presented in red.

Figure 2. Clinical consultation rate for ILI per 100,000 practice population in Welsh sentinel practices (Week 50 1996 – Week 16 2024).



* Reporting changed to Audit+ surveillance system

Table 1. Age-specific consultations (per 100,000) for ILI in Welsh sentinel practices, Week 11 – Week 16 2024 (as of 21/04/2024).

Age group	11	12	13	14	15	16
< 1	0.0	0.0	0.0	0.0	0.0	0.0
1 - 4	0.0	0.0	0.0	6.7	0.0	0.0
5 - 14	4.6	2.4	0.0	0.0	2.3	3.0
15 - 24	4.4	2.2	4.4	4.2	6.7	8.2
25 - 34	13.7	16.2	6.0	5.7	7.9	12.4
35 - 44	13.1	11.6	9.6	9.0	1.9	2.4
45 - 64	4.6	6.7	5.7	7.2	4.7	2.4
65 - 74	2.2	2.3	2.2	2.1	4.4	5.8
75+	4.3	4.5	6.7	0.0	8.7	5.7
Total	6.3	6.5	5.0	4.7	4.9	5.0

Table 2. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, Week 11 – Week 16 2024 (as of 21/04/2024).

Age group	11	12	13	14	15	16
< 1	1277.0	1625.4	701.0	1101.8	961.2	614.0
1 - 4	1093.5	893.2	556.2	583.3	639.0	625.7
5 - 14	486.7	497.8	236.4	249.8	327.5	311.8
15 - 24	190.4	192.6	155.4	137.4	186.3	128.7
25 - 34	219.0	234.2	139.7	147.1	172.7	154.0
35 - 44	198.6	214.7	149.1	184.2	136.9	182.7
45 - 64	197.5	178.5	130.7	154.2	179.0	139.6
65 - 74	185.6	158.1	140.0	164.2	185.6	170.9
75+	248.3	185.0	157.4	218.5	187.8	159.4
Total	274.2	259.5	171.1	195.9	212.7	190.0

Figure 3. Age-specific consultations (per 100,000) for ARI in Welsh sentinel practices, Week 16 2023 – Week 16 2024.






Figure 4. Specimens submitted for virological testing by sentinel GPs and community pharmacies as of 21/04/2024, by week of sample collection, Week 16 2023 to Week 16 2024.



* Tested negative for influenza, adenovirus, rhinovirus, RSV, parainfluenza, mycoplasma, human metapneumovirus, enterovirus, bocavirus and coronaviruses. Samples which test positive for more than one pathogen will appear more than once in the chart. **Results for the latest week will underestimate activity as not all samples will have been received, tested, and authorised at time of writing this report. Additionally, week 13 includes Bank Holiday Friday, where general practices would have been closed.**

Figure 5. Specimens submitted for virological testing for hospital patients and non-sentinel GPs as of 21/04/2024 by week of sample collection, Week 16 2023 to Week 16 2024.



This chart summarises respiratory panel test data and does not include data for patients tested SOLELY for SARS-CoV2. Combined data for tests carried out in Public Health Wales Microbiology: Cardiff laboratory, provided by Public Health Wales Microbiology Cardiff Specialist Virology Centre. This chart summarises individual test results, patients who are positive for multiple infections within a given week will appear multiple times. Samples which test positive for more than one pathogen will appear more than once in the chart.

Figure 6. Flu subtypes based on specimens submitted for virological testing by sentinel GPs and community pharmacies, hospital patients, and non-sentinel GPs, as of 21/04/2024 by week of sample collection, Week 16 2023 to Week 16 2024.




Figure 7. Specimens from hospital patients submitted for RSV, Influenza and SARS-CoV2 testing only, as of 21/04/2024 by week of sample collection, Week 16 2023 to Week 16 2024.






Figure 8. Specimens submitted for virological testing for ICU patients, by week of sample collection, Week 16 2023 to Week 16 2024.



This chart summarises respiratory panel test data and does NOT include data for patients tested SOLELY for SARS-CoV2. Samples which test positive for more than one pathogen will appear more than once in the chart.

Figure 9. RSV incidence rate per 100,000 population aged under five years, week 30 2019 to Week 16 2024.



*RSV seasons are monitored from W30 to W29, the most recent data is presented in red

ARI – Hospital admissions

Figure 10. Seven day rolling sum of cases hospitalised in Wales within 28 days of an influenza positive test result in the community (or up to 2 days post-admission), as of 21/04/2024.




Figure 11. Seven day rolling sum of cases hospitalised in Wales within 28 days of an RSV positive test result in the community (or up to 2 days post-admission), as of 21/04/2024.






Figure 12. Seven day rolling sum of cases hospitalised in Wales within 28 days of an Covid-19 positive test result in the community (or up to 2 days post-admission), as of 21/04/2024.



Calls to NHS Direct Wales

Figure 13. Influenza related calls to NHS Direct Wales¹ (as a percentage of total calls) from Week 16 2020 - Week 16 2024.



¹ Data supplied by Health Statistics and Analysis Unit, Welsh Government.

Flu related calls are the sum of calls recorded as 'cold/flu', 'cough', 'headache', 'fever' and 'sore throat'. Following changes to the NHS Direct calls system, including the start of the 111 pilot, there has been a change in the way in which denominator data are calculated for this chart, NHS Direct Wales now count the total number of nurse triaged calls (i.e. calls which could have symptom data recorded against them), note that 111 includes out-of-hours calls.

Influenza Vaccine Uptake in Wales

Table 3. Uptake of influenza immunisations in GP Practice patients in Wales 2023/24 (as of 09/04/2024).

Influenza immunisation uptake in the 2023/24 season	
People aged 65y and older	72.4%
People younger than 65y in a clinical risk group	39.1%
Children aged two & three years	42.9%
Children aged between four & ten years	61.9%
Children aged between 11 & 15 years	49.7%
Total NHS staff	38.2%
NHS staff with direct patient contact	38.3%

The end of season report Influenza in Wales 2019/20 is available to download and contains a full breakdown of vaccination uptake amongst eligible groups.
Link to report: <https://phw.nhs.wales/topics/immunisation-and-vaccines/flu vaccine/annual-influenza-surveillance-and-influenza-vaccination-uptake-reports/>

Influenza activity – UK and international summary

- As of Week 15, GP ILI consultations remained stable at 3.3 per 100,000 in England and increased to 7.23 per 100,000 in Scotland.
- During Week 15, 6,041 samples testing positive for influenza were reported in England of which 163 were positive for influenza (74 influenza A(not subtyped), 45 influenza A(H3N2), 12 influenza A(H1N1)pdm09, and 32 influenza B). Overall influenza positivity decreased to 2.7% in England and to 3.2 per 100,000 in Scotland in week 15.
- UK summary data are available from the [UKHSA Influenza and COVID-19 Surveillance Report](#) and [COVID-19 & Respiratory Surveillance \(shinyapps.io\)](#)
- The WHO and the European Centre for Disease Prevention and Control (ECDC) reported during week 15, that influenza positivity continues to decrease and is now below the 10% positivity epidemic threshold. Of the 34 countries and areas reporting on influenza intensity, one reported high intensity, five reported medium intensity, 14 reported low intensity and the remainder reported baseline intensity. Of the 33 countries and areas reporting on geographic spread of influenza viruses within a country or area, eight reported widespread, five reported regional, four reported local, and 16 reported sporadic activity. As of week 15, there were 63 confirmed influenza virus infection detections reported from sentinel primary care, 72% of which were influenza B viruses.
Source: European Respiratory Virus Surveillance Summary (ERVISS): <https://erviss.org/>
- The WHO reported on 17/04/2024, based on data up to 07/04/2024 that influenza activity continues to decrease, though the predominant circulating virus is influenza B.
- In the temperate zones and of the Northern Hemisphere influenza activity continued to decline.
- In the temperate zones of the southern hemisphere, influenza activity remained low with a few exceptions in South America, where influenza activity increased with predominantly influenza A detections. **Source:** WHO influenza update: <https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-updates/current-influenza-update>
- Based on FluNet reporting (as of 15/04/2024), during the period from 05/04/2024 – 17/04/2023 National Influenza Centres and other national influenza laboratories from 139 countries, areas or territories reported influenza surveillance data. The WHO Global Influenza Surveillance and Response System laboratories tested more than 558,758 specimens during that period, of which 65,337 were positive for influenza viruses, 37,790 (57.8%) were typed as influenza A (of the subtyped influenza A viruses, 5,798 (47.2%) were influenza A(H1N1)pdm09 and 6,486 (52.8%) were influenza A(H3N2). Of the 65,337 samples testing positive for influenza viruses, 27,547 tested positive for Influenza B (42.2%). **Source:** Flu Net: <https://www.who.int/tools/flunet>

Update on influenza activity in North America

- The USA Centers for Disease Control and Prevention (CDC) report that influenza activity continues to decline in most areas of the country (ending 15/04/2024). Nationally, 3,569 specimens have tested positive for influenza during week 15 in clinical laboratories nationwide, of these positive samples, 1,929 (54.0%) were influenza A and 1,640 (46.0%) were influenza B. Further characterisation has been carried out on 962 specimens by public health laboratories, 210 samples tested positive for influenza; 43 influenza A(H1N1)pdm09, 58 influenza A(H3N2), 40 influenza A(not subtyped) and 79 influenza B.
Source: CDC Weekly US Influenza Surveillance Report: <http://www.cdc.gov/flu/weekly/>
- The Public Health Agency of Canada reported that during week 15, influenza activity declined compared to the previous week. During week 15, 2,254 influenza detections were reported: 525 influenza A, and 1,729 influenza B. The percentage of ILI visits was 0.9%. **Source:** Public Health Agency of Canada: <https://www.canada.ca/en/public-health/services/diseases/flu-influenza/influenza-surveillance/weekly-influenza-reports.html>

Respiratory syncytial virus (RSV) in North America

- The USA CDC reported that the RSV positivity rate slightly decreased in the week beginning 13/04/2024.
Source: CDC RSV national trends: <https://www.cdc.gov/surveillance/nrvss/rsv/natl-trend.html>

COVID-19 – UK and international summary

- As of 17/04/2024, there were 1.8 new positive PCR episodes per 100,000 population in Wales, for the most recent 7-day reporting period. Latest COVID-19 data from Public Health Wales is available from: <https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/>
- The latest UKHSA COVID-19 data summary is available from: <https://coronavirus.data.gov.uk/>
- WHO situation updates on COVID-19 are available from: <https://covid19.who.int/>

Middle East respiratory syndrome coronavirus (MERS-CoV) – latest update from WHO and ECDC

- Since the beginning of 2023 and as of 01 February 2024, a total of 2200 human cases have been reported, including 858 deaths. Overall, human infections of MERS-CoV have been reported from 27 countries, in all six WHO regions. Of the 2609 MERS-CoV cases and 939 deaths reported globally, 84% and 91%, respectively, have been reported from KSA, including these newly reported cases and deaths. (Figure 2). Since 2019, no MERS-CoV cases have been reported from countries outside the Middle East. WHO Global Alert and Response website: <https://www.who.int/emergencies/disease-outbreak-news>
- Since the 05 February and as of 12 February 2024, four new MERS-CoV cases, including two fatalities have been reported by Saudi Arabia.
- Rapid risk assessments of the situation from ECDC, which contain epidemiological updates and advice for travellers and healthcare workers, are available from: <https://ecdc.europa.eu/en/middle-east-respiratory-syndrome-coronavirus>
- Further updates and advice for healthcare workers and travellers are available from WHO: <http://www.who.int/emergencies/mers-cov/en/> and from NaTHNaC: <https://travelhealthpro.org.uk/news/237/mers-cov-update-travelhealthpro-country-pages>

Human infection with avian influenza A(H7N9), China

- The latest WHO Influenza at Human-Animal Interface summary reports that there have been no publicly available reports from China or other countries on influenza A(H7N9) in recent months, but overall risk assessments are unchanged. Previous reports are available from: <https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary>
The risk of international spread of avian influenza A(H7N9) is considered to be low at present. However, it is important that clinicians are aware of the possibility of human infection with animal influenza, in persons presenting with severe acute respiratory disease, while travelling or soon after returning from an area where avian influenza is a concern. WHO Global Alert & Response updates: <https://www.who.int/emergencies/disease-outbreak-news>

Links:

Public Health Wales influenza surveillance webpage:

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=25480>

Public Health Wales COVID-19 data dashboard:

<https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-19/>

Public Health Wales interactive report on hospitalisations in influenza and RSV cases:

<https://public.tableau.com/app/profile/public.health.wales.health.protection/viz/ARI-Hospitaladmissionsdashboard/ARIHospitaladmissionsdashboard?publish=yes>

GP Sentinel Surveillance of Infections Scheme:

<http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=27918>

NICE influenza antiviral usage guidance:

<http://www.nice.org.uk/Guidance/TA158>

England influenza and COVID-19 surveillance:

<https://www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2023-to-2024-season>

Scotland seasonal respiratory surveillance:

<https://www.publichealthscotland.scot/publications>

Northern Ireland influenza surveillance:

<https://www.publichealth.hscni.net/directorate-public-health/health-protection/seasonal-influenza>

European Centre for Communicable Disease:

<http://ecdc.europa.eu/>

European influenza information:

<http://flunewseurope.org/>

Advice on influenza immunisation

<https://phw.nhs.wales/topics/immunisation-and-vaccines/flu vaccine/>

Advice on influenza immunisation (for intranet users)

[Influenza \(sharepoint.com\)](#)

For further information on this report, please email Public Health Wales using:

surveillance.requests@wales.nhs.uk